Mäenpää J, Grönroos M, Leppänen M, Kangas L
Cancer. 1984 Oct 15;54(8):1530-4. doi: 10.1002/1097-0142(19841015)54:8<1530::aid-cncr2820540810>3.0.co;2-x.
The predictive value of the subrenal capsule (SRC) assay for cancer chemotherapy was tested in five rat tumors. Tumor-bearing rats were used as controls. In order to simulate clinical chemotherapy, different dose regimens and drug combinations were used. All five tumors were evaluable in in the SRC assay. Taking into account cytotoxic drugs, 86% compatibility was obtained between the SRC assay and the rat model. Antitumor effect of three antiestrogenic compounds could not be predicted by the SRC assay. It is concluded that the SRC assay can be expected to have predictive value in the assessment of tumor sensitivity to single and combination chemotherapy based on experimental animal models.
在五种大鼠肿瘤中测试了肾包膜下（SRC）试验对癌症化疗的预测价值。荷瘤大鼠用作对照。为了模拟临床化疗，使用了不同的剂量方案和药物组合。所有五种肿瘤在SRC试验中均可评估。考虑到细胞毒性药物，SRC试验与大鼠模型之间的相容性为86%。三种抗雌激素化合物的抗肿瘤作用无法通过SRC试验预测。得出的结论是，基于实验动物模型，SRC试验有望在评估肿瘤对单一和联合化疗的敏感性方面具有预测价值。
